eCureMe logo
  eCureMe home eCureMe log In Sign Up!
eCureMe Life : Your Healthy Living. Click Here!
Welcome, eCureMe.com medical contents search April 25, 2013
       eCureMe Life
       Medical Supplies
       Calorie Count
       Self-Diagnosis
       Physician Search
       Message Board
      E-mail Doctor
      E-mail Veterinarian
      Self-Diagnosis
      Health-O-Matic Meter
      Calorie Count
      Natural Medicine
      Vitamins & Minerals
      Alternative Living
      My Health Chart
      Diseases & Treatments
      Atlas of Diseases
      Sexually Transmitted
      Diseases
      Drug Information
      Illegal Drugs
      Lab & Diagnostic Tests
      Internal Medicine
      Women’s Health
      Pediatrics
      Eye Disorders
      Skin Disorders
      Headache
      Mental Health
      Radiology
      Neurology
      Allergy
      Resource Links
      Physician Directory
      Dentist Directory
      Hospital Directory





Abstral (Fentanyl)


Central nervous system agent


Analgesic


Breakthrough pain. Opioid therapy for underlying persistent cancer pain.


1. Adults: initially one 100mcg dose; if adequate analgesia is obtained within 30 min, continue to treat subsequent episodes with this dose. If inadequate, give 2nd dose after 30 min. For future episodes, if analgesia is not obtained with 100mcg dose, titrate in increments of 100mcg up to 400mcg as needed; if 400mcg is inadequate, titrate to 600mcg dose, then 800mcg dose if needed. May use 100mcg or 200mcg tablets for any single dose; max 4 tabs at one time. Max 2 doses/episode, up to 4 episodes/day. Wait at least 2 hrs before treating another episode. Wait at least 2 hrs before treating another episode. Maintenance: use only one tablet of appropriate strength. 2. Children: Under age of 18: not recommended.


Category C


Nause, drowsiness, headache, headache, constipation, respiratory/circulatory depression.


Pregnancy Risk Categories defined:

A: Studies in pregnant women failed to show a risk to the fetus in the first trimester - with no evidence of risk in the later trimesters.

B: Animals studies indicate no adverse effect to the fetus, but there are no adequate, clinical studies in pregnant women.

C: Animal studies have shown an adverse effect on the fetus, but there are no adequate, clinical studies in humans. Despite potential risks, the drug may be useful in pregnant women.

D: There is evidence of risk to the human fetus, but the potential benefits of use in pregnant women may be acceptable, despite potential risks.

X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any potential benefit from using the drug in pregnant women, regardless of trimester.

NR: Not rated (i.e., no information available at this time as to the potential risks or benefits).










If you want your friend to read or know about this article, Click here






medical contents search

Home   |   About Us   |   Contact Us   |   Employment Ad   |   Help

Terms and Conditions under which this service is provided to you. Read our Privacy Policy.
Copyright © 2002 - 2003 eCureMe, Inc All right reserved.